Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 174

1.

Effects of Janus kinase inhibitor tofacitinib on circulating serum amyloid A and interleukin-6 during treatment for rheumatoid arthritis.

Migita K, Izumi Y, Jiuchi Y, Kozuru H, Kawahara C, Izumi M, Sakai T, Nakamura M, Motokawa S, Nakamura T, Kawakami A.

Clin Exp Immunol. 2014 Feb;175(2):208-14. doi: 10.1111/cei.12234.

2.

Tofacitinib in combination with nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: a randomized trial.

Kremer J, Li ZG, Hall S, Fleischmann R, Genovese M, Martin-Mola E, Isaacs JD, Gruben D, Wallenstein G, Krishnaswami S, Zwillich SH, Koncz T, Riese R, Bradley J.

Ann Intern Med. 2013 Aug 20;159(4):253-61. doi: 10.7326/0003-4819-159-4-201308200-00006.

PMID:
24026258
3.

In vitro and in vivo analysis of a JAK inhibitor in rheumatoid arthritis.

Tanaka Y, Maeshima K, Yamaoka K.

Ann Rheum Dis. 2012 Apr;71 Suppl 2:i70-4. doi: 10.1136/annrheumdis-2011-200595. Erratum in: Ann Rheum Dis. 2013 Jan;72(1):156. Maeshima, Y [corrected to Maeshima, K].

PMID:
22460142
4.

JAK inhibitor tofacitinib for treating rheumatoid arthritis: from basic to clinical.

Tanaka Y, Yamaoka K.

Mod Rheumatol. 2013 May;23(3):415-24. doi: 10.1007/s10165-012-0799-2. Epub 2012 Dec 5. Review.

PMID:
23212593
5.

The JAK inhibitor tofacitinib suppresses synovial JAK1-STAT signalling in rheumatoid arthritis.

Boyle DL, Soma K, Hodge J, Kavanaugh A, Mandel D, Mease P, Shurmur R, Singhal AK, Wei N, Rosengren S, Kaplan I, Krishnaswami S, Luo Z, Bradley J, Firestein GS.

Ann Rheum Dis. 2015 Jun;74(6):1311-6. doi: 10.1136/annrheumdis-2014-206028. Epub 2014 Nov 14.

6.

Tofacitinib, an oral Janus kinase inhibitor: analysis of malignancies across the rheumatoid arthritis clinical development programme.

Curtis JR, Lee EB, Kaplan IV, Kwok K, Geier J, Benda B, Soma K, Wang L, Riese R.

Ann Rheum Dis. 2016 May;75(5):831-41. doi: 10.1136/annrheumdis-2014-205847. Epub 2015 Apr 22.

7.

Cost-effectiveness of Tofacitinib in the Treatment of Moderate to Severe Rheumatoid Arthritis in South Korea.

Lee MY, Park SK, Park SY, Byun JH, Lee SM, Ko SK, Lee EK.

Clin Ther. 2015 Aug;37(8):1662-76.e2. doi: 10.1016/j.clinthera.2015.07.001. Epub 2015 Aug 1.

PMID:
26243076
8.

Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs.

Fleischmann R, Cutolo M, Genovese MC, Lee EB, Kanik KS, Sadis S, Connell CA, Gruben D, Krishnaswami S, Wallenstein G, Wilkinson BE, Zwillich SH.

Arthritis Rheum. 2012 Mar;64(3):617-29. doi: 10.1002/art.33383.

9.

Tofacitinib: The First Janus Kinase (JAK) inhibitor for the treatment of rheumatoid arthritis.

Vyas D, O'Dell KM, Bandy JL, Boyce EG.

Ann Pharmacother. 2013 Nov;47(11):1524-31. doi: 10.1177/1060028013512790. Review.

PMID:
24285764
10.

Tofacitinib or adalimumab versus placebo in rheumatoid arthritis.

van Vollenhoven RF, Fleischmann R, Cohen S, Lee EB, GarcĂ­a Meijide JA, Wagner S, Forejtova S, Zwillich SH, Gruben D, Koncz T, Wallenstein GV, Krishnaswami S, Bradley JD, Wilkinson B; ORAL Standard Investigators.

N Engl J Med. 2012 Aug 9;367(6):508-19. doi: 10.1056/NEJMoa1112072. Erratum in: N Engl J Med. 2013 Jul 18;369(3):293.

11.

Tofacitinib versus methotrexate in rheumatoid arthritis.

Lee EB, Fleischmann R, Hall S, Wilkinson B, Bradley JD, Gruben D, Koncz T, Krishnaswami S, Wallenstein GV, Zang C, Zwillich SH, van Vollenhoven RF; ORAL Start Investigators.

N Engl J Med. 2014 Jun 19;370(25):2377-86. doi: 10.1056/NEJMoa1310476.

12.

Tofacitinib, an oral Janus kinase inhibitor, as monotherapy or with background methotrexate, in Japanese patients with rheumatoid arthritis: an open-label, long-term extension study.

Yamanaka H, Tanaka Y, Takeuchi T, Sugiyama N, Yuasa H, Toyoizumi S, Morishima Y, Hirose T, Zwillich S.

Arthritis Res Ther. 2016 Jan 28;18:34. doi: 10.1186/s13075-016-0932-2.

13.

Tofacitinib for treatment of rheumatoid arthritis.

Rakieh C, Conaghan PG.

Adv Ther. 2013 Aug;30(8):713-26. doi: 10.1007/s12325-013-0047-y. Epub 2013 Aug 14. Review.

PMID:
23943546
14.

Tofacitinib in the Treatment of Rheumatoid Arthritis and Chronic Plaque Psoriasis.

Gupta AK, Cernea M, Lynde CW.

Skin Therapy Lett. 2017 Mar;22(2):1-7. Review.

15.

Influence of Janus kinase inhibition on interleukin 6-mediated induction of acute-phase serum amyloid A in rheumatoid synovium.

Migita K, Koga T, Komori A, Torigoshi T, Maeda Y, Izumi Y, Sato J, Jiuchi Y, Miyashita T, Yamasaki S, Kawakami A, Nakamura M, Motokawa S, Ishibashi H.

J Rheumatol. 2011 Nov;38(11):2309-17. doi: 10.3899/jrheum.101362. Epub 2011 Aug 15.

PMID:
21844139
16.

Recent progress and perspective in JAK inhibitors for rheumatoid arthritis: from bench to bedside.

Tanaka Y.

J Biochem. 2015 Sep;158(3):173-9. doi: 10.1093/jb/mvv069. Epub 2015 Jul 7. Review.

PMID:
26152731
17.

A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone.

Kremer JM, Cohen S, Wilkinson BE, Connell CA, French JL, Gomez-Reino J, Gruben D, Kanik KS, Krishnaswami S, Pascual-Ramos V, Wallenstein G, Zwillich SH.

Arthritis Rheum. 2012 Apr;64(4):970-81. doi: 10.1002/art.33419. Epub 2011 Oct 17.

18.
19.

Tofacitinib: a review of its use in adult patients with rheumatoid arthritis.

Scott LJ.

Drugs. 2013 Jun;73(8):857-74. doi: 10.1007/s40265-013-0065-8. Review. Erratum in: Drugs. 2013 Sep;73(14):1647.

PMID:
23716132
20.

Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis.

Fleischmann R, Kremer J, Cush J, Schulze-Koops H, Connell CA, Bradley JD, Gruben D, Wallenstein GV, Zwillich SH, Kanik KS; ORAL Solo Investigators.

N Engl J Med. 2012 Aug 9;367(6):495-507. doi: 10.1056/NEJMoa1109071.

Supplemental Content

Support Center